GHP Q2 2024 was crucial in advancing their product to Phase III clinical trials.” Sean explains. Speaking on the future, Sean excitedly tells us, “Our goal is to be the premier CDMO/CRO partner for biopharmaceutical companies, offering unparalleled expertise and seamless, streamlined endto-end services that ensure their products reach the market efficiently and effectively. Outside of our innovative technologies and platforms, we are taking the necessary steps to support our customer’s commercial scale programs in both San Diego, CA and Bristol, PA. With a robust commercialization readiness plan in place, we will be PPQ production ready in 2025. Judging from the innovative platforms Abzena have launched over the years, it is certain that the future is bright for the industry pioneer. We eagerly anticipate the next advancements from Abzena as the company continues to solidify its position as an industry leader. If you are interested in reading about the latest advancements in biotechnology from Abzena, visit the company website today. Company Contact: Kimberly Burrell, SVP of Global Marketing Email: [email protected] Website: www.abzena.com and evaluate any potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics. We asked Sean to describe the improvements made to the platform and he tells us, “The EpiScreen® 2.0 platform offers advanced capabilities in predicting and migrating immunogenicity, a critical factor in the success of biopharmaceutical products. The enhanced features of EpiScreen® 2.0 will enable us to provide more accurate immunogenicity assessments, helping our customers de-risk their development programs and accelerate the path to clinical trials and market approval.” Abzena is also considered to be a pioneer in the bioconjugation space with their next generation site-specific conjugation technology, ThioBridge™. When developing Antibody-drug conjugates, or ADCs, linker technologies are a pivotal element to consider. Many linkers, especially those used in the development of first-generation ADC bioconjugation, have limitations that can have an adverse effect on the safety and effectiveness of the ADC. Abzena has designed and implemented ThioBridge™ to overcome such limitations that may arise with traditional linker technologies. “ThioBridge utilizes the native interchain disulphide bonds of an antibody to conjugate an array of linker payloads, ensuring a consistent and stable drug-to-antibody ratio. This technology allows for more consistent dosing, better control of pharmacokinetics, and more flexibility in choosing the drug type and linker. This means that our customers benefit from a more efficient and reliable pathway to developing ADCs. We have had customers say that our expertise in ADC programs, combined with ThioBridge technology,
RkJQdWJsaXNoZXIy MTUyMDQwMA==